{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:09Z","timestamp":1793677269607,"version":"4.5.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.seminhematol.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T19:47:22Z","timestamp":1678132042000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Infectious complications of chimeric antigen receptor (CAR) T-cell therapies"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-7172","authenticated-orcid":false,"given":"Juan C.","family":"Gea-Banacloche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0004","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR T-cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/imed.1036","article-title":"Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T-cell therapy","volume":"2","author":"Zhou","year":"2022","journal-title":"ImmunoMedicine"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0007","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA Adverse Event Reporting System (FAERS) Database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0013","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0017","doi-asserted-by":"crossref","first-page":"18741","DOI":"10.18632\/aging.104058","article-title":"A comprehensive analysis of the fatal toxic effects associated with CD19 CAR T-cell therapy","volume":"12","author":"Cai","year":"2020","journal-title":"Aging"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0018","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","article-title":"Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis","volume":"20","author":"Telli Dizman","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T Cell therapy: a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jha2.350","article-title":"CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias","volume":"3","author":"Taneja","year":"2022","journal-title":"EJHaem"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0021","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0022","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0023","first-page":"1","article-title":"Antibodies against vaccine-preventable infections after CAR T-cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0025","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0026","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0028","first-page":"739","article-title":"Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days","volume":"42","author":"Li","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0029","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T-cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR T-cells","volume":"62","author":"Wittmann","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0032","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0033","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0034","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0035","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0036","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0038","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0039","doi-asserted-by":"crossref","first-page":"e2295","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0040","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1097\/MJT.0000000000001487","article-title":"Secondary infection risk in patients with severe COVID-19 pneumonia treated with tocilizumab","volume":"29","author":"Sandhu","year":"2022","journal-title":"Am J Ther"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0041","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0043","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","author":"Laetsch","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMcps2114818","article-title":"Confused about confusion","volume":"386","author":"Spanjaart","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0046","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12185-020-02840-x","article-title":"Progressive multifocal leukoencephalopathy after CAR T therapy","volume":"112","author":"Sdrimas","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0047","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13583","article-title":"Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy","volume":"106","author":"Mian","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0048","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/s41375-020-0952-4","article-title":"The efficacy and safety of CAR T-cell therapy in patients with refractory ALL and concomitant HBV infection","volume":"34","author":"Lai","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0049","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR T-cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0051","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2807","article-title":"Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection","volume":"39","author":"Cui","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0052","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","article-title":"Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T-cells for the treatment of diffuse large B-cell lymphoma","volume":"7","author":"Wei","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0053","article-title":"Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0054","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0055","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0056","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T-cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0057","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Advances"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0058","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2022016855","article-title":"Buckling up against COVID-19 after CAR T-cell therapy","volume":"140","author":"Auletta","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0059","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0060","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229946","article-title":"Unexpected neurologic complications following a novel lymphoma treatment \u201cexpected\u201d to give rise to neurologic toxicity","volume":"12","author":"Kersten","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0062","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1473-3099(19)30119-7","article-title":"Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy","volume":"19","author":"Marzolini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0063","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/bjh.16402","article-title":"Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy","volume":"189","author":"Kator","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0064","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4269\/ajtmh.21-0246","article-title":"Case report: refractory cryptosporidiosis after CAR T-cell therapy for lymphoma","volume":"105","author":"Trottier","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0066","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0067","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","article-title":"Prevention and management of infections in patients undergoing CAR T-cell therapy: recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"108","author":"Paul","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0068","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0069","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR T-cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0071","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0072","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ijc.33356","article-title":"Filgrastim associations with CAR T-cell therapy","volume":"148","author":"Gaut","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0073","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Li\u00e9vin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0074","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T-cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0075","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/cid\/ciaa031","article-title":"Chimeric antigen receptor T-cell immunotherapy and need for prophylaxis for invasive mold infections","volume":"71","author":"Lewis","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0076","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12879-020-05755-4","article-title":"Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy: a case report","volume":"21","author":"Rejeski","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.seminhematol.2023.02.003_bib0077","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciaa032","article-title":"Reply to Lewis and Kontoyiannis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:45Z","timestamp":1758522525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0037196323000197"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.02.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}